|Videos|September 9, 2020

Laser Therapy for Severe COVID-19 Pneumonia

An examination of a patient presenting with the condition in the early days of the pandemic without the access to current care protocols.

Scott Sigman, MD, fellow, Royal College of Surgeons in Ireland, is an orthopedic surgeon who is the first to tell you he did not expect to be on the front lines of the COVID-19 crisis. Yet he became the principal investigator for a case involving a patient with severe COVID-19 who developed pneumonia.

In the early days of the pandemic, hospitals were getting besieged with cases and they were grappling to find treatments. Sigman's background in using laser therapy for othopedic therapy put him in front of this patient. The patient was admitted to the ICU of a hospital in Lowell, Massachusetts for respiratory distress and in need of oxygenation.

The patient was not able to ambulate and rather than put the patient on a ventilator they decided to try photobiomodulation therapy (PBMT). Sigman treated the patient with a once-daily, 28-minute PBMT sessions for 4 days using an FDA approved multiwave locked system therapy laser.

The patient's respiratory indices, radiological findings, oxygen requirements and outcomes improved over several days and without the need for a ventilator.

This case was written up in the American Journal of Case Reports.

Sigman spoke with Contagion® about using the therapy, the patient's outcome, and future studies looking at this for prospective patients who present with a similar diagnosis.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.